Performance of the Freestyle Libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: A secondary outcome analysis of a randomized crossover trial

被引:62
作者
Moser, Othmar [1 ,2 ,3 ]
Eckstein, Max L. [1 ,2 ,3 ]
McCarthy, Olivia [1 ,2 ]
Deere, Rachel [1 ,2 ,4 ]
Pitt, Jason [1 ,2 ]
Williams, David M. [2 ]
Hayes, Jennifer [2 ]
Sourij, Harald [3 ]
Bain, Stephen C. [2 ]
Bracken, Richard M. [1 ,2 ]
机构
[1] Swansea Univ, Sch Med, Diabet Res Grp, Swansea, W Glam, Wales
[2] Swansea Univ, Coll Engn, Appl Sport Technol Exercise & Med Res Ctr A STEM, Swansea, W Glam, Wales
[3] Med Univ Graz, Div Endocrinol & Diabetol, Graz, Austria
[4] Univ Bath, Dept Hlth, Bath, Avon, England
基金
欧盟地平线“2020”;
关键词
continuous glucose monitoring (CGM); exercise intervention; hypoglycaemia; type; 1; diabetes; SENSING TECHNOLOGY; PHYSICAL-EXERCISE; REAL-TIME; MULTICENTER;
D O I
10.1111/dom.13835
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The efficacy of flash glucose monitoring (flash GM) systems has been demonstrated by improvements in glycaemia; however, during high rates of glucose flux, the performance of continuous glucose monitoring systems was impaired, as detailed in previous studies. This study aimed to determine the performance of the flash GM system during daily-life glycaemic challenges such as carbohydrate-rich meals, bolus insulin-induced glycaemic disturbances and acute physical exercise in individuals with type 1 diabetes. Materials and methods This study comprised four randomized trial visits with alternating pre- and post-exercise bolus insulin doses. Throughout the four 14-hour inpatient phases, 19 participants received three carbohydrate-rich meals and performed moderate-intensity exercise. Venous blood glucose and capillary blood glucose during exercise was compared to interstitial glucose concentrations. Flash GM accuracy was assessed by median absolute relative difference (MARD) (interquartile range [IQR]) using the Bland-Altman method and Clark error grid, as well as according to guidelines for integrated CGM approvals (Class II-510(K)). Results The overall MARD (IQR) during inpatient phases was 14.3% (6.9%-22.8%), during hypoglycaemia (<= 3.9 mmol/L) was 31.6% (16.2%-46.8%), during euglycaemia (4.0 mmol/L - 9.9 mmol/L) was 16.0% (8.5%-24.0%) and during hyperglycaemia (>= 10 mmol/L) was 9.4% (5.1%-15.7%). Overall Bland-Altman analysis showed a bias (95% LoA) of 1.26 mmol/L (-1.67 to 4.19 mmol/L). The overall MARD during acute exercise was 29.8% (17.5%-39.8%), during hypoglycaemia was 45.1% (35.2%-51.1%), during euglycaemia was 30.7% (18.7%-39.2%) and during hyperglycaemia was 16.3% (10.0%-22.8%). Conclusion Flash GM interstitial glucose readings were not sufficiently accurate within the hypoglycaemic range and during acute exercise and require confirmatory blood glucose measurements.
引用
收藏
页码:2505 / 2512
页数:8
相关论文
共 21 条
[1]   Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes [J].
Aberer, Felix ;
Hajnsek, Martin ;
Rumpler, Markus ;
Zenz, Sabine ;
Baumann, Petra M. ;
Elsayed, Hesham ;
Puffing, Adelheid ;
Treiber, Gerlies ;
Pieber, Thomas R. ;
Sourij, Harald ;
Mader, Julia K. .
DIABETES OBESITY & METABOLISM, 2017, 19 (07) :1051-1055
[2]  
[Anonymous], 2017, DIABETES CARE S1, V40, pS48
[3]   Accuracy of continuous glucose monitoring during differing exercise conditions [J].
Bally, Lia ;
Zueger, Thomas ;
Pasi, Nicola ;
Carlos, Ciller ;
Paganini, Daniela ;
Stettler, Christoph .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 112 :1-5
[4]   AN ENDOCRINE CLINIC'S PERSPECTIVE AND EXPERIENCE WITH THE ABBOTT FREESTYLE LIBRE CGM [J].
Blum, James R. ;
Rayfield, Elliot J. .
ENDOCRINE PRACTICE, 2018, 24 (03) :309-311
[5]   Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial [J].
Bolinder, Jan ;
Antuna, Ramiro ;
Geelhoed-Duijvestijn, Petronella ;
Kroeger, Jens ;
Weitgasser, Raimund .
LANCET, 2016, 388 (10057) :2254-2263
[6]   International Consensus on Use of Continuous Glucose Monitoring [J].
Danne, Thomas ;
Nimri, Revital ;
Battelino, Tadej ;
Bergenstal, Richard M. ;
Close, Kelly L. ;
DeVries, J. Hans ;
Garg, Satish ;
Heinemann, Lutz ;
Hirsch, Irl ;
Amiel, Stephanie A. ;
Beck, Roy ;
Bosi, Emanuele ;
Buckingham, Bruce ;
Cobelli, Claudio ;
Dassau, Eyal ;
Doyle, Francis J., III ;
Heller, Simon ;
Hovorka, Roman ;
Jia, Weiping ;
Jones, Tim ;
Kordonouri, Olga ;
Kovatchev, Boris ;
Kowalski, Aaron ;
Laffel, Lori ;
Maahs, David ;
Murphy, Helen R. ;
Norgaard, Kirsten ;
Parkin, Christopher G. ;
Renard, Eric ;
Saboo, Banshi ;
Scharf, Mauro ;
Tamborlane, William V. ;
Weinzimer, Stuart A. ;
Phillip, Moshe .
DIABETES CARE, 2017, 40 (12) :1631-1640
[7]  
Dover Anna R, 2017, J Diabetes Sci Technol, V11, P442, DOI 10.1177/1932296816661560
[8]   Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring [J].
Edelman, Steven V. ;
Argento, Nicholas B. ;
Pettus, Jeremy ;
Hirsch, Irl B. .
DIABETES CARE, 2018, 41 (11) :2265-2274
[9]   A New Era in Continuous Glucose Monitoring: Food and Drug Administration Creates a New Category of Factory-Calibrated Nonadjunctive, Interoperable Class II Medical Devices [J].
Garg, Satish K. ;
Akturk, H. Kaan .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (06) :391-394
[10]   Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial [J].
Haak, Thomas ;
Hanaire, Helene ;
Ajjan, Ramzi ;
Hermanns, Norbert ;
Riveline, Jean-Pierre ;
Rayman, Gerry .
DIABETES THERAPY, 2017, 8 (01) :55-73